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Here, we find that human-induced pluripotent stem
cell (hiPSC)-derived cardiomyocyte (CM)-fated pro-
genitors (CFPs) that express a tetraspanin family
glycoprotein, CD82, almost exclusively differentiate
into CMs both in vitro and in vivo. CD82 is transiently
expressed in late-stage mesoderm cells during
hiPSC differentiation. Purified CD82+ cells gave rise
to CMs under nonspecific in vitro culture conditions
with serum, as well as in vivo after transplantation
to the subrenal space or injured hearts in mice, indi-
cating that CD82 successfully marks CFPs. CD82
overexpression inmesoderm cells as well as in undif-
ferentiated hiPSCs increased the secretion of exo-
somes containing b-catenin and reduced nuclear
b-catenin protein, suggesting that CD82 is involved
in fated restriction to CMs through Wnt signaling in-
hibition. This study may contribute to the under-
standing of CM differentiation mechanisms and to
cardiac regeneration strategies.
INTRODUCTION
Differentiation of pluripotent stem cells (PSCs) to a specific cell
type is a process that involves the loss of differentiation potential
toward other cell fates. Recent efficient cardiomyocyte (CM) dif-
ferentiation protocols clarified CM differentiation mechanisms
and provided cell types at various differentiation stages (Bur-
ridge et al., 2012, 2014). PSCs such as embryonic stem cells
(ESCs) and induced PSCs (iPSCs) are induced to themesoderm,
subsequently restricted to cardiac mesoderm composed of car-
diovascular progenitor cells (CPCs), and finally committed to
CMs. However, there is a missing link during the fate determina-
tion process between CPCs and CMs, that is, when and how the
CPC fate is restricted to CMs is poorly understood. CPCs that
differentiate into CM, endothelial cell (EC), and vascular smooth
muscle cell (SMC) lineages have been identified in mice and
humans. CPCs have been characterized by the expression of
several transcriptional factors, including NK2 homeobox5
(Nkx2.5), Islet1 (Isl1), and mesoderm posterior basic helix-
loop-helix transcription factor 1 (Mesp1). In addition, several
cell-surface markers have been implicated, including C-X-C
chemokine receptor type 4 (CXCR4), receptor tyrosine kinase-
like orphan receptor 2 (ROR2), CD13, hyperpolarization-acti-
vated cyclic nucleotide-gated channel 4 (HCN4), stage-specific
embryonic antigen 1 (SSEA1), glial cell line-derived neurotrophic
factor (GDNF) family (GFRA2), kinase insert domain receptor
(KDR), and platelet-derived growth factor receptor-a (PDGFRa)
(Ardehali et al., 2013; Blin et al., 2010; Burridge et al., 2012;
Ishida et al., 2016; Kattman et al., 2011; Moretti et al., 2006;
Spa¨ter et al., 2013; Wu et al., 2006; Yamashita et al., 2000,
2005; Yang et al., 2008). Recently, CPCs were directly reprog-
rammed from fibroblasts (Lalit et al., 2016; Zhang et al., 2016).
CPCs derived from PSCs hold great promise for the study of
cardiovascular development as well as for cardiac regeneration.
Although CPCs differentiate into CMs with high efficiency in
optimized CM differentiation culture conditions in vitro, they
also show differentiation toward non-CM populations such as
vascular or other stromal cell lineages under nonspecific culture
conditions or after transplantation in vivo (Lalit et al., 2016;
Yamashita, 2016). Putative cell populations that exclusively
differentiate into CMs even in diverse microenvironments
in vitro and in vivo (here called CM-fated progenitors [CFPs])
are anticipated but remain unknown. Previously, using mouse
PSCs, we established amethod to systematically induce cardio-
vascular cells from Flk+ mesoderm cells (Narazaki et al., 2008;
Yamashita et al., 2000, 2005). Using human iPSCs (hiPSCs),
we reported methods for efficient CM and simultaneous cardio-
vascular cell differentiation (Masumoto et al., 2014; Uosaki et al.,
2011) based on a high-density monolayer culture for human
ESCs (Laflamme et al., 2007). In the present study, utilizing our
hiPSC differentiation technology, we sought to identify CFPs
from hiPSCs.
We defined the timing of CM fate determination during hiPSC
differentiation and identified CD82 as a cell-surface marker
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Figure 1. Identification of CD82 as a Candidate Cell-Surface Marker for CFPs
(A) Representative flow cytometric analysis of cTnT, PDGFRb, and VCAM1. Purified KP-d 3, 4 and 5 were recultured for 14 days in the absence of Wnt inhibitors
under serum-free (RPMI1640+B27 supplement) or serum conditions (RPMI1640+10% FBS). Numbers in the quadrants represent the respective percentages of
cells.
(B) Quantitative analysis of (A). Data are means ± SDs.
*p < 0.05, **p < 0.01 by one-way ANOVA followed by Tukey’s post hoc test (n = 4).
(legend continued on next page)
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specifically expressed at the time. CD82 belongs to the tetraspa-
nin family of glycoproteins andwasfirst identified asametastasis-
suppressor gene of prostate cancer (Dong et al., 1995). CD82 is
reported to function in cell adhesion, motility and invasion, tumor
cell senescence, and exosome production and secretion (Tsai
andWeissman, 2011). CD82+ cells overwhelmingly differentiated
intoCMs in vitroand in vivo. Moreover, we founda role for CD82 in
CM differentiation: Wnt signal inhibition through exosome-medi-
ated b-catenin excretion. Thus, we succeeded in identifying a
human CFP population and CM differentiation mechanism.
RESULTS
Identification of CD82 as a Candidate Cell-Surface
Marker for CFPs
To identify specific markers of CFPs, we used a previously re-
ported serum-free high-density monolayer culture protocol for
hiPSC differentiation to CMs (Uosaki et al., 2011) with minimal
modifications (see Experimental Procedures). We analyzed the
temporal expression pattern of two representative CPC surface
markers, KDR and PDGFRa, and found that the KDR+PDGFRa+
(KP) population (Kattman et al., 2011; Yang et al., 2008) promi-
nently emerged from day 3 and peaked at day 5 in our system.
To evaluate the cardiomyogenic potential of the KP population
at different stages, we purified the KP population at days 3, 4,
and 5 by fluorescence-activated cell sorting (FACS) and recul-
tured the purified populations for 14 days in the absence of
Wnt inhibitions (see Reculture Experiments) under serum-free
condition (RPMI1640+B27 supplement) or under serum condi-
tion (RPMI1640+10% fetal bovine serum [FBS]) that permits
diverse differentiation (Figures 1A, 1B, and S1A). In serum-free
condition, the KP population at day 3 (KP-d3) efficiently gave
rise to CMs (cardiac troponin T [cTnT+]) as well as PDGFRb+ peri-
cyte/mesenchymal cell (PC/MC) populations. KP-d4 and -d5
gave rise to more CMs and fewer PC/MCs than did KP-d3, sug-
gesting that the KP population possesses differentiation poten-
tial to both CMs and PC/MCs and that the CM differentiation
potential was enhanced at days 4 and 5. In serum condition,
even though KP-d3 and -d4 possess CM differentiation potential
in serum-free condition, KP-d3 and -d4 almost completely failed
to differentiate into CMs, with >90% of the cells differentiating
into PDGFRb+cTnT PC/MCs. Alternatively, KP-d5 predomi-
nantly differentiated into CMs, even with serum (Figures 1A
and 1B). These results indicate that the restriction of the fate
determination to CMs in the KP population in this differentiation
protocol occurs during days 4 to 5 of differentiation and that
CFPs, which robustly differentiate into CMs even under serum
condition, may presumably be included in KP-d5. These results
are compatible with a previous study that showed insulin/insulin-
like growth factor, which is found in serum, blocked CM differen-
tiation during an early mesoderm stage (Freund et al., 2008).
To identify candidate cell-surface markers of CFPs in KP-d5,
we employed a comprehensive analysis of global gene expres-
sion during differentiation days 3–5. We compared gene expres-
sion profiles among undifferentiated hiPSCs; purified KP-d3,
-d4, -d5; and CMs induced from KP-d5 (Figure S1B). We identi-
fied 6 genes encoding cell-surface markers that showed signifi-
cantly high deviation from the mean expression level of all genes
on days 3, 4, or 5: integrin a5 chain (ITGA5; CD49e), kangai-1
(KAI1; CD82), PDGFRa (CD140a), tumor necrosis factor receptor
superfamily 11A (TNFRSF11A; CD265), KDR (CD309), and
jagged 1 (JAG1; CD339) (Figure 1C). Among them, only CD82
demonstrated a unique temporal change in its expression
pattern, because it was upregulated >4-fold from days 4 to 5
and appeared to be significantly deviated from day 5, suggesting
that CD82 is a potent candidate marker of CFPs. We examined
the time course of CD82 expression during CM differentiation
using flow cytometry. The CD82+ population started to be
observed from day 4, its percentage increased until day 7
(>60% at maximum), and gradually decreased thereafter (Fig-
ure 1D). The distinct appearance of the CD82+ population within
the PDGFRa+ population at day 5 supported the possibility that
CD82 is a specific cell-surface marker for CFPs.
CD82 Successfully Marks CFP Population In Vitro
Next, we examined the possibility that CD82 marks CFPs. We
purified CD82+ and CD82 cells among the PDGFRa+CD13+
CPC population (Ardehali et al., 2013) from days 3 to 7 by
FACS (Figures S1C and S1D). From days 3 to 4, CD82 cells
alone were purified; from day 5, both CD82 and CD82+ cells
were purified; and from days 6 to 7, CD82+ cells alone were pu-
rified from PDGFRa+CD13+ cells. We recultured the purified
populations without Wnt inhibitors and tested the differentiation
potential and commitment of these populations toward CMs un-
der serum-free or serum culture conditions. Under serum-free
condition, CD82 cells (days 3–5) yielded cTnT+ CMs with
50%–75% efficiency, and CD82+ cells (days 5–7) yielded
cTnT+ CMs with 80%–95% efficiency. The rest of the cells
were mainly PDGFRb+cTnT PC/MCs. These results indicate
that both the CD82+ and CD82 populations in PDGFRa+CD13+
CPCs are potentially cardiomyogenic (Figures 2A and 2B). Under
serum condition, CD82 cells did not differentiate into CMs;
instead they predominantly differentiated into PDGFRb+cTnT
PC/MCs, indicating that CD82 cells can be differentiated into
CM or non-CMs depending on the culture environment. Alterna-
tively, CD82+ cells predominantly differentiated into CMs
independent of the culture conditions even with serum (Figures
2A and 2B). Of note, CD82 cells and CD82+ cells at day 5
showed apparently distinct fate determination under serum
condition. Immunostaining also showed that most CD82 cells
at day 5 differentiated into nonbeating calponin+ PC/MCs,
whereas most CD82+ cells differentiated into cTnT+ CMs with
(C) Scattered dot plot analysis for the distribution of 288 CD genes at days 3, 4, and 5. The y axis is the log2 expression of the genes in the purified KP population.
The x axis is the log2 ratio of the genes in the purified KP population comparedwith their average expression in undifferentiated iPSCs andCMs. The contour lines
reflect the density of the gene distributions. ITGA5 (CD49e), KAI1 (CD82), PDGFRa (CD140a), TNFRSF11A (CD265), KDR (CD309), and JAG1 (CD339) showed
significantly high deviations from the mean expression level of all genes on days 3, 4, or 5. Red dot indicates CD82.
(D) Representative flow cytometric analysis for CD82 and PDGFRa from days 0 to 15. Numbers in the quadrants represent the respective percentages of cells.
See also Figures S1A and S1B.
548 Cell Reports 22, 546–556, January 9, 2018
spontaneous beating even in serum condition (Figure 2C;Movies
S1 and S2).
To further confirm the robustness of CD82+ cells as CFPs
restricted to CM fate, we examined CD82+ cell differentiation
to ECs. We purified KDR+ cells among the PDGFRa+ population,
which was reported to possess EC differentiation potential
(Ikuno et al., 2017; Prasain et al., 2014), segregated the KDR+
cells into CD82 and CD82+ cells, and cultured each population
in an EC-oriented culture condition containing vascular endothe-
lial cell growth factor (VEGF) from day 5 (Figures S1E–S1G). In
the no-VEGF condition, both CD82 and CD82+ populations
differentiated into VE-cadherin+ ECs at 1% efficiency. In
contrast, the induction of ECs from the CD82 population was
increased by the addition of VEGF, but the EC appearance





Figure 2. CD82 Successfully Marks CFP Pop-
ulation In Vitro
(A) Representative flow cytometric analysis of cTnT,
PDGFRb, and VCAM1. Purified CD82 or CD82+
populations among the PDGFRa+CD13+ CPC
population from days 3 to 7 were recultured for
14 days in the absence of Wnt inhibitors under
serum-free (RPMI1640+B27 supplement) or serum
condition (RPMI1640+10% FBS). Numbers in the
quadrants represent the respective percentages of
cells.
(B) Quantitative analysis of (A). Data are means ±
SDs. *p < 0.05, **p < 0.01 by one-way ANOVA fol-
lowed by Tukey’s post hoc test (n = 3).
(C) Representative image of cTnT (green), calponin
(red), and DAPI (blue) in differentiated cells derived
from purified CD82 or CD82+ populations among
the PDGFRa+CD13+ CPC population at day 5
after 14 days’ reculture under serum condition
(RPMI1640+10% FBS) in the absence of Wnt
inhibitors. DAPI, 40,6-diamidino-2-phenylindole.
Scale bars, 100 mm.
(D) Immunostaining of Isl1 (red), Nkx2.5 (green), and
DAPI (blue) in purified CD82 or CD82+ populations
among the PDGFRa+CD13+ CPC population from
days 5 to 7. Scale bars, 20 mm.
(E) Quantitative analysis of Isl1+ and Nkx2.5+ cells
per nucleus in (D). Data are means ± SDs. *p < 0.05,
**p < 0.01 by one-way ANOVA followed by Tukey’s
post hoc test (n = 5).
See also Figures S1C–S1G and S2–S4.
S1G). These results indicated that CD82+
cells no longer responded to EC differenti-
ation cues.
We further compared CD82 expression
with other mesoderm lineage markers.
Two transcription factors, Isl1 and Nkx
2.5, which characterize CPCs (Moretti
et al., 2006; Prall et al., 2007; Wu et al.,
2006), were expressed in the majority of
both CD82+ and CD82 populations (Fig-
ures 2D and 2E). CD82 cells largely ex-
pressed Isl1 or Nkx2.5, suggesting that
these transcription factors should be able
to endow cardiomyogenic potential, but they do not immediately
determine lineage commitment to CMs. The time course of CD82
expression revealed that CD82 is a CMprogenitor stage-specific
gene. CD82 expression and the CM markers cTnT and/or
vascular cell adhesion molecule 1 (VCAM1) (Uosaki et al.,
2011) at day 11 were largely mutually exclusive (Figure S2A),
indicating that CD82 is expressed during the CM progenitor
stage, but not in CMs. The expression of signal regulatory pro-
tein-a (SIRPA) (Dubois et al., 2011; Elliott et al., 2011) in meso-
derm cells was first observed after CD82 expression (from
day 7) and was gradually increased and maintained on CMs at
day 11 (Figure S2B). The appearance (day 3) and peak (day 5)
of CD13 expression preceded those of CD82. Most CD82+
cells were CD13+ until day 7 (Figure S2C). ThemRNA expression
time course further confirmed that CD82 is a CM progenitor
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stage-restricted gene (Figure S2D) that is upregulated later than
mesoderm genes (CD13, PDGFRa) and downregulated earlier
than CM genes (SIRPA, VCAM1). All of these results indicate
that CD82 is specifically expressed at the CM progenitor stage
(late mesoderm before CMs) and determines single fate-
restricted differentiation to CMs. One CD82+ CFP was estimated
to give rise to 5.8 CMs after 14 days of reculture (Figure S2E).
Action potentials of the CFP-derived CMs demonstrated that
CFPs mainly give rise to ventricular-like CMs (action potential
duration [APD]30-40/APD70-80 >1.5) with few nodal-like CMs
(APD30-40/APD70-80 %1.5, dV/dt max < 10 V/s) (Ma et al.,
2011) (Figures S3A and S3B). We examined the expression of
CD82 and the cardiomyogenic potential of CD82 and CD82+
cells in 2 other cell lines, 836B3 and 1201C1 (established by
the episomal plasmid vector) (Okita et al., 2011, 2013) (Figure S4).
Although the time course of the CM differentiation was slightly
delayed in 836B3 and 1201C1 (Figures S4A and S4D), the
CD82 expression pattern was almost similar to that in 201B6.
Also similar to 201B6, CD82+ cells in 836B3 and 1201C1
predominantly differentiated into CMs rather than into CD90+
PC/MCs even under serum condition (Figures S4B, S4C, S4E,
and S4F). These results indicate that CD82 can be used to
isolate CFPs regardless of the original cell line or differentiation
timing.
CD82+ CFPs Overwhelmingly Give Rise to CMs In Vivo
To examine the CM-restricted differentiation of CD82+ CFPs
in vivo, we injected one of three different cell populations from
hiPSCs (CD13+CD82 CPCs at day 4, VCAM1+ CMs at day 15,
or CD82+ CFPs at day 6) into the subrenal space of severe com-
bined immunodeficiency (SCID) mice, which is a completely un-
related and independent environment from the heart (Figure 3A).
Immunohistochemical staining with human nuclear antigen
(HNA) (for all injected human cells) and cTnT at 1 or 2 weeks after
injection revealed almost no engraftment of HNA+ human cells
after the injection of CD13+CD82 CPCs (Figure 3B). Although
a small number of VCAM1+ CMs remained 1 week after injection
(Figure 3B), the injected cells (HNA+) disappeared 2 weeks after
injection (data not shown). In contrast, much greater engraftment
of HNA+cTnT+ human CMs was observed after the injection of
CD82+ CFPs (Figures 3B–3D). More than 99% of HNA+ cells
were positive for cTnT after the CD82+ CFP injection (Figure 3C).
These data indicate that CD82+ CFPs survived well and almost
exclusively differentiated into CMs even in a nonspecific environ-
ment in vivo. Next, we examined the engraftment of CD82+ CFPs
to infarcted hearts. We injected CD82+ (PDGFRa+CD13+) CFPs
into the heart of a myocardial infarction model of nonobese dia-
betic (NOD)/NOD.Cg-Prkdcscid IL2rgtm1Sug/Jic (NOG) immu-
nodeficient mice (Figure 3E). HNA+cTnT+ human CM clusters
were successfully detected at 1 and 3 months after transplanta-
tion (Figure 3F). Striated sarcomeric structures, although still
immature, formed in HNA+cTnT+ human CMs at 3 months after
transplantation, suggesting structural maturation of the en-
grafted CMs (Figure 3J). Consistent with the results of the
subrenal transplantation, CFPs primarily differentiated into
CMs within the infarcted hearts at 95% efficiency (1 month,
95.9% ± 2.4%; 3 months, 93.7% ± 2.7%) (Figure 3G). Fewer
than 5% of neural/glial antigen 2 (NG2)+ PCs were observed 1
and 3 months after transplantation (1 month, 3.6 ± 3.2%;
3 months, 2.3 ± 2.1%) (Figures 3H and 3I). These results indicate
that hiPSC-derived CD82+ CFPs can give rise predominantly to
CMs after transplantation to the infarcted hearts, implying their
application as a stable cardiomyogenic cell source for cardiac
regeneration.
Exosome-Mediated Wnt/b-Catenin Signal Control
through CD82 Expression
Next, we investigated the biological function of CD82 in CM dif-
ferentiation. CD82 is recognized as an exosome marker. Addi-
tionally, it was reported to antagonize Wnt/b-catenin activity
through the exosomal clearance of b-catenin from the cells
(Chairoungdua et al., 2010). Wnt inhibition is known to potently
induce differentiation and commitment to CMs from mesoderm
cells (Naito et al., 2006; Yamashita et al., 2005). We speculated
that CM commitment in CD82+ cells may be regulated byWnt in-
hibition through exosomal b-catenin clearance.
To test this hypothesis, we performed CD82 overexpression
experiments. We established an hiPSC line carrying a tetracy-
cline-inducible CD82/enhanced green fluorescent protein
(EGFP) double-expressing vector based on the piggyBac trans-
poson system (Woltjen et al., 2009) (Figure 4A). Doxycycline
treatment (Dox+) in the hiPSC line robustly induced CD82/
EGFP expression (Figures 4B and 4C). We collected the culture
supernatant and the nuclear and cytoplasmic fractions of cells
treated under Dox+ or Dox- conditions. Although the cell number
was significantly lower in Dox+ condition (Figure 4D), the number
of exosome particles was approximately 5.2 times higher in
Dox+ supernatant than that in Dox- (Figures 4E and 4F). Western
blot analysis adjusted to the exosome number revealed that
b-catenin was much more highly contained in Dox+ exosomes
compared to Dox- exosomes (Figure 4G), suggesting that
CD82 overexpression enhanced the secretion of exosomes con-
taining b-catenin. Although no clear difference was observed in
the b-catenin level in the cytoplasm (Figure 4H), nuclear b-cate-
nin protein was significantly decreased in Dox+ cells (Figure 4I).
In addition, canonical Wnt signal activity was significantly
reduced in Dox+ cells (Figure 4J).
Functional Significance of CD82 Expression during CM
Differentiation from CPCs
Finally, we investigated the biological function of CD82 in CMdif-
ferentiation from mesoderm cells. We performed CD82 overex-
pression experiments in PDGFRa+ CPCs at day 5 (Figure 5A).
Purified PDGFRa+ cells were recultured with serum under one
of the following conditions for 2 days (days 5–7): (1) Dox- (nega-
tive control), (2) Dox- with Wnt inhibitors (XAV 5 mM + IWP4
2.5 mM) (positive control), or (3) Dox+ with no Wnt inhibitors.
CD82 expression was successfully induced by Dox+ (Figures
5B and 5C). Wnt signal activation was significantly suppressed
by either Wnt inhibitors or CD82 overexpression (Dox+) (Fig-
ure 5D). We collected the culture supernatant and the nuclear
and cytoplasmic fractions of cells. The increase in the number
of exosome particles in Dox+ supernatant was approximately
3.6 and 2.8 times higher than that in Dox- and Dox- with Wnt in-
hibitors supernatants, respectively (Figures 5E and 5F). Western
blot analysis adjusted by the exosome number revealed that
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b-catenin and CD82 were much more contained in Dox+ exo-
somes compared to those in Dox- or Dox- with Wnt inhibitor-
treated exosomes (Figures 5G and 5H), indicating that CD82
overexpression contributed to the increase in exosome-medi-
ated b-catenin secretion. Although no clear difference was
observed in b-catenin levels in the cytoplasm among the 3
groups (Figure 5I), the nuclear b-catenin protein level was signif-
icantly decreased in Dox+ or Dox- with Wnt inhibitor-treated
cells (Figure 5J). We further confirmed that CM differentiation
at 14 days after reculture was significantly enhanced by CD82
overexpression (Figures 5K and 5L). These results suggest a bio-
logical function of CD82 in cardiomyogenesis from PDGFRa+
cells; i.e., CD82 attenuates Wnt signaling through the exosomal
clearance of nuclear b-catenin in CPCs, resulting in augmented
CM differentiation through commitment to CMs.
DISCUSSION
In the present study, we found that human CFPs, a hiPSC-
derived cell population that almost exclusively differentiates
into CMs under diverse conditions in vitro and in vivo, are
marked by the cell-surface molecule CD82. Furthermore,
we found that CD82 contributes to CM differentiation by attenu-
ating the Wnt/b-catenin signaling pathway through exosomal
regulation.
The significance of CFPs is schematically shown in Figure 6.
The differentiation potential of undifferentiated PSCs is broad
over three germ layer cells. Even though PSCs can give rise to
CMs in CM-specific culture conditions, they can be differenti-
ated into all germ layer derivatives in vivo (nonspecific condi-









Figure 3. CD82+ CFPs Overwhelmingly Give
Rise to CMs In Vivo
(A) Schematic representation of the cell trans-
plantation into subrenal space of SCID mice.
CD13+CD82 CPCs at day 4, CD82+ CFPs at day 6,
or VCAM1+ CMs at day 15 were purified with
MACS and transplanted. Kidneys were collected
2 weeks after transplantation (CD13+CD82 CPCs
and CD82+ CFPs) or 1 week after transplantation
(VCAM1+ CMs).
(B) Representative images of cTnT (green), human
nuclear antigen (HNA (red). and DAPI (blue)
staining after transplantation of CD13+CD82CPCs
(2 weeks), CD82+ CFPs (2 weeks), and VCAM1+
CMs (1 week). White dashed lines indicate the in-
jected region. Scale bars, 200 mm.
(C) Higher magnification image of cTnT (green), HNA
(red), and DAPI (blue) after transplantation of CD82+
CFPs. Note that almost all of the HNA+-transplanted
cells are positive for cTnT. Scale bar, 200 mm.
(D) cTnT-positive area after transplantation of
CD13+CD82 CPCs, CD82+ CFPs, or VCAM1+
CMs. N.D., not detected. Data are means ± SDs.
*p < 0.05 by Mann-Whitney test (n = 4, 5 different
slides per animal, 4 animals).
(E) Schematic representation of the transplantation
of FACS-purified CD82+ CFPs (PDGFRa+CD13+)
into the heart of a myocardial infarction model of
NOG immunodeficient mice. Hearts were collected
1 and 3 months after transplantation.
(F) Representative image of cTnT (green), HNA (red),
and DAPI (blue) staining 3 months after the trans-
plantation of CD82+ CFPs. Scale bar, 50 mm.
(G) Percentage of cTnT+ cells among HNA+ cells at
1 and 3 months after transplantation. Data are
means ± SDs (n = 3, 4 different slides per animal,
3 animals).
(H) Representative image of NG2 (green), HNA (red),
and DAPI (blue) staining 3 months after the trans-
plantation of CD82+ CFPs. Scale bar, 50 mm.
(I) Quantification of NG2+ cells per HNA+ cells at
1 and 3 months after transplantation. Data are
means ± SDs (n = 3, 4 different slides per animal,
3 animals).
(J) Higher magnification image of cTnT (green), HNA
(red), and DAPI (blue) staining 3 months after
transplantation of CD82+ CFPs. Sarcomere-like
structure is observed. Scale bar, 5 mm.
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differentiation potential to mesoderm cell lineages, which largely
give rise to CMs under CM-specific culture conditions. Never-
theless, in nonspecific conditions, CPCs exhibit broader differ-
entiation capacity, resulting in the appearance of various
mesoderm derivatives that may not include CMs (Lalit et al.,
2016; Yamashita, 2016). In contrast to undifferentiated PSCs
or CPCs, CD82+ CFPs have privileged differentiation potential
in which the direction of differentiation is almost exclusively
limited to CMs even under nonspecific conditions and in vivo.
Consequently, CD82+ CFPs can differentiate into CMs specif-
ically and stably in vivo after transplantation.
The identification of cell-surface markers associated with car-
diomyogenic potential has been a high priority in cardiac regen-
eration research because of the potential broad application of
cells without genetic modification (Anderson et al., 2007).
Although numerous cell-surface markers, including ROR2,
CD13, HCN4, SSEA1, GFRA2, KDR, and PDGFRa, have been
identified during hiPSC differentiation toward CMs, all of these
markers specified mesoderm cells or CPCs that give rise
not only to CMs but also to non-CMs, including vascular cells
or stromal cells (Ardehali et al., 2013; Blin et al., 2010; Burridge
et al., 2012; Ishida et al., 2016; Kattman et al., 2011; Spa¨ter
et al., 2013; Yang et al., 2008). SIRPA is another cell-surface
marker reported to be expressed on CMs and CM progenitor
populations (Dubois et al., 2011; Elliott et al., 2011). However,
the exclusive differentiation of SIRPA+ progenitors to CMs is
still unclear. In addition, SIRPA is expressed in both CM
progenitors and CMs. Thus, the present study successfully dem-
onstrates a cell-surface marker, CD82, that identifies the CFP
population. With the use of CD82, we can easily detect and
obtain a pure human cell population that specifically gives rise
to CMs.
In contrast to previous reports that demonstrated fair engraft-
ment of CPCs as well as CMs into hearts (Chong et al., 2014;
Laflamme et al., 2007), we observed no or poor engraftment of
CD13+CD82CPCs and VCAM1+ CMs in subrenal space. These
results may suggest that CM engraftment, survival, and differen-








Figure 4. Exosome-Mediated Wnt/b-Catenin
Signal Control through CD82 Expression
(A) Construct of the Tet-inducible CD82/EGFP ex-
pressing piggyBac vector (PB-TetO-CD82/EGFP
vector).
(B) Representative flow cytometric analysis of EGFP
and CD82 (Alexa Fluor 647) expression in the iPSC
line under doxycycline (Dox)+ or Dox- condition for
3 days. Numbers in the quadrants represent the
respective percentages of cells.
(C) Quantitative analysis of CD82+ cells under Dox+
or Dox- condition for 3 days. Data are means ± SDs.
*p < 0.05 by Mann-Whitney test (n = 4).
(D) Cell numbers under Dox+ or Dox- condition for
3 days. Cells at subconfluency in a 10-cm dish were
exposed to Dox+ or Dox- condition for 3 days. Data
are means ± SDs. *p < 0.05 by Mann-Whitney test
(n = 5).
(E) Representative exosome particle number and
size distribution under Dox+ or Dox- condition for
3 days. The x axis indicates particle diameter
(nanometers), and the y axis indicates particle
concentration (3 1010/mL). Particle size distribution
and particle concentration were analyzed after ul-
tracentrifugation. Blue and red boxes indicate exo-
some particles under Dox+ or Dox- condition,
respectively, for 3 days.
(F) Exosome numbers in 1 mL of supernatant under
Dox+ or Dox- condition for 3 days. Total number
of exosomes was calculated by multiplying the
measured exosome concentration by the volume
and then dividing by the initially collected superna-
tant volume (8 mL). Data are means ± SDs. *p < 0.05
by Mann-Whitney test (n = 5).
(G) b-Catenin in exosomes. Representative western
blot of b-catenin in an exosome (left panel) and
quantitative evaluation of b-catenin intensity under
Dox+ or Dox- condition (right panel). Sample
loading amounts were adjusted with exosome numbers. A.U., arbitrary units. *p < 0.05 by Mann-Whitney test (n = 5).
(H) Representative western blot of b-catenin in the cytoplasmic fraction (left panel) and b-catenin intensity normalized to b-actin under Dox+ or Dox- condition
(right panel). *p < 0.05 by Mann-Whitney test (n = 3).
(I) Representative western blot of b-catenin in the nuclear fraction (left panel) and b-catenin intensity normalized to Lamin A/C under Dox+ or Dox- condition (right
panel). *p < 0.05 by Mann-Whitney test (n = 4).
(J) Canonical Wnt signal activity. TOP-FLASH/FOP-FLASH ratio with or without Dox. *p < 0.05 by Mann-Whitney test (n = 9).
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sites. Even when injected into subrenal space, which is unlikely a
niche dedicated to cardiac cell lineages, CD82+ CFPs engrafted
as CMs, suggesting that CD82+ CFPs may possess robust
adaptability to various microenvironments. Although a previous
report found a podoplanin-positive cardiac progenitor popula-
tion mainly differentiated into pacemaker-like cells (Birket
et al., 2015), CD82+ CFPs predominantly differentiated into ven-











Figure 5. Functional Significance of CD82
Expression during CM Differentiation from
CPCs
(A) Schematic protocol for recultured experiments
of purified PDGFRa+ populations at day 5 derived
from an hiPSC line carrying a tetracycline-inducible
CD82/EGFP double-expressing vector. Purified
PDGFRa+ mesoderm cells were recultured with
serum (10% FBS) under one of the following con-
ditions for 2 days (days 5–7): (1) Dox- (negative
control), (2) Dox- with Wnt inhibitors (XAV 5 mM +
IWP4 2.5 mM) (positive control), or (3) Dox+ with no
Wnt inhibitors.
(B) Representative flow cytometric analysis of EGFP
and CD82 (Alexa Fluor 647) expression in the puri-
fied PDGFRa+ population under Dox+, Dox-, or Wnt
inhibitors condition for 2 days. Numbers in the
quadrants represent the respective percentages of
cells.
(C) Quantitative analysis of CD82+ cells in (B). Data
are means ± SDs. **p < 0.01 by one-way ANOVA
followed by Tukey’s post hoc test (n = 5).
(D) Canonical Wnt signal activity. TOP-FLASH/FOP-
FLASH under Dox+, Dox-, or Wnt inhibitors condi-
tion for 2 days. Data are means ± SDs. **p < 0.01,
*p < 0.05 by one-way ANOVA followed by Tukey’s
post hoc test (n = 9).
(E) Representative exosome particle number and
size distribution under Dox+, Dox-, or Wnt inhibitors
condition for 2 days. The x axis indicates particle
diameter (nanometers), and the y axis indicates
particle concentration (3 109/mL). Particle size
distribution and particle concentration were
analyzed after ultracentrifugation. Black, blue, red,
and green boxes indicate exosome particles in
medium (RPMI1640+10% FBS), Dox+, Dox-, or Wnt
inhibitors condition for 2 days, respectively.
(F) Exosome numbers in 1 mL of supernatant of
medium (RPMI1640+10% FBS), Dox+, Dox-, or Wnt
inhibitors condition for 2 days. Total number of
exosome was calculated by multiplying the
measured exosome concentration by the volume
and then dividing by the initial collected supernatant
volume (4 mL). Dashed line indicates the number of
exosomes in the medium. Data are means ± SDs.
*p < 0.05 by Mann-Whitney test (n = 4).
(G) b-Catenin in exosomes. Representative western
blot of b-catenin in an exosome (upper panel) and
quantitative evaluation of b-catenin intensity in Dox+, Dox-, or Wnt inhibitors condition for 2 days (lower panel). Sample loading amounts were adjusted with the
exosome number. A.U., arbitrary units. *p < 0.05, **p < 0.01 by one-way ANOVA post hoc Tukey’s test (n = 4).
(H) CD82 in exosomes. Representative western blot of b-catenin in an exosome (upper panel) and quantitative evaluation of b-catenin intensity in Dox+, Dox-, or
Wnt inhibitors condition for 2 days (lower panel). Sample loading amounts were adjusted with the exosome number. A.U., arbitrary units. *p < 0.05, **p < 0.01 by
one-way ANOVA post hoc Tukey’s test (n = 4).
(I) Representative western blot of b-catenin and b-actin in the cytoplasmic fraction (upper panels) and b-catenin intensity normalized to b-actin in Dox+, Dox-, or
Wnt inhibitors condition for 2 days (lower panel) (n = 5).
(J) Representative western blot of b-catenin and Lamin A/C in the nuclear fraction (upper panels) and b-catenin intensity normalized to Lamin A/C in Dox+, Dox-,
or Wnt inhibitors condition for 2 days (lower panel). *p < 0.05, **p < 0.01 by one-way ANOVA followed by Tukey’s post hoc test (n = 9).
(K) Representative flow cytometric analysis of EGFP and cTnT expression 14 days after reculture. Numbers in the quadrants represent the respective per-
centages of cells.
(L) Quantitative analysis of cTnT+ cells in (L). Data are means ± SDs. *p < 0.05, **p < 0.01 by one-way ANOVA followed by Tukey’s post hoc test (n = 7).
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to compensate damaged myocardium. Taking these results
together, although further refinement of the transplantation effi-
ciency in combination with other cell and tissue transplantation
technologies is required, CD82+ CFPs may serve as a potential
candidate for cardiac regenerative cell therapy.
Recently, CD82 was reported to be expressed on hemato-
poietic stem cells and skeletal muscle satellite cells (Alexander
et al., 2016; Hur et al., 2016; Uezumi et al., 2016). However,
the involvement of Wnt signaling and exosome regulation
in CD82 function was not described in those reports. In
addition, CD82 was expressed in completely different devel-
opmental stages and tissues from CFPs, suggesting that
previously described CD82+ populations are different from
the population reported here and have distinct functions.
Wnt inhibition is crucial for the CM commitment process (Naito
et al., 2006; Yamashita et al., 2005). The present study
suggests a molecular mechanism in which CD82-mediated
exosomal regulation contributes to CM fate determination.
In addition, we show that the expression of the cardiac tran-
scription factors Isl1 and Nkx2.5 is still insufficient to exclu-
sively determine CM fate (Figures 2D and 2E), suggesting
that other mechanisms, including epigenetic regulation, are
required. The molecular and mechanical links among CD82,
exosome, and epigenome are critical research targets for
future study.
In conclusion, CD82may provide a valuable clue to elucidating
the CM fate determination process and offers an efficient way to
prepare an almost pure CFP population from human PSCs. Our
findings broadly extend to basic and applied stem cell biology in
the cardiac field.
EXPERIMENTAL PROCEDURES
Further details are given in the Supplemental Experimental Procedures.
Figure 6. Differentiation Spectrum of PSCs,
CPCs, and CD82+ CFPs
Schematic diagrams of the differentiation potential
spectrum (blue, all rows) and differentiation abilities
under CM-specific (yellow, middle row) or nonspe-
cific conditions, including after in vivo trans-
plantation (purple, bottom row). Undifferentiated
PSCs (left column), CPCs (central column) and
CD82+ CFPs (right column) are shown. Note that
only CFPs, whose differentiation potential is
restricted to CMs, can overwhelmingly differentiate
into CMs even under nonspecific conditions.
Human iPSC Culture and CM Differentiation
The hiPSC line 201B6 (4 factors [Oct3/4, Sox2, Klf4,
and c-Myc] from skin adult fibroblast) (Takahashi
et al., 2007) was used as a representative human
iPSC line in all of the experiments unless stated
otherwise. The hiPSCs maintenance culture method
was reported previously (Laflamme et al., 2007;
Masumoto et al., 2014; Uosaki et al., 2011).
The CM differentiation protocol also was reported
previously (Laflamme et al., 2007; Masumoto
et al., 2014; Uosaki et al., 2011), with minimal mod-
ifications. We used RPMI1640+B27 supplement
(insulin+) medium from day 5, instead of RPMI1640+B27 supplement without
insulin (insulin-) medium.
Reculture Experiments
Differentiated cells were recultured in the absence of Wnt inhibitions under
serum-free condition (RPMI1640+B27 supplement [insulin+] or under serum
condition (RPMI1640+10% FBS) with the addition of 10 mM Y-27632 (Wako;
for the first 2 days after plating) and penicillin and streptomycin (Meiji Seika
Pharma). The culture medium was refreshed every 2 days (Figures 1 and 2).
Microarray Analysis
RNA was extracted from undifferentiated iPSCs; purified KP cells at days 3, 4,
and 5, and CMs derived from KP cells at day 5 under serum condition
(Figure S1B) using the RNeasy Mini Kit (Qiagen). Total RNA was reverse tran-
scribed into cDNA via SuperScript II Reverse Transcriptase (Life Technolo-
gies). Samples were labeled with Cy3 using the BioArray HighYield RNA
Transcript Labeling Kit (T7) (Enzo Life Sciences). Labeled cDNA was hybrid-
ized with Human Genome U133 Plus 2.0 Array by the GeneChip Hybridization
Control Kit and the GeneChip Fluidics Station 450 (all Affymetrix) at 45C for
16 hr. Arrays were scanned with the GeneChip Scanner 3000 7G according
to the manufacturer’s protocol and analyzed using GeneChip operating soft-
ware (both Affymetrix). The raw data were normalized using the MAS5 algo-
rithm (median score of the gene expressions: 500).
Animal Model Preparation and Transplantation
All of the animal experiments were approved by the Kyoto University Animal
Experimentation Committee and performed in accordance with the guidelines
for Animal Experiments of Kyoto University, which conforms to Japanese law
and the Guide for the Care and Use of Laboratory Animals.
Male immunodeficient mice (SCID C.B17/lcr-scid/scid Jcl mice [CLEA
Japan] or NOG, CLEA Japan) aged 8–12 weeks were used for transplantation
into subrenal space or hearts of a myocardial infarction model. Then, 2 3 106
CD82+ CFPs purified with FACS were suspended in 20 mL RPMI1640 medium
and injected into the left ventricular myocardium directly after left anterior de-
scending (LAD) coronary ligation of NOG mice. Finally, 53 106 CD13+ CD82
CPCs, CD82+ CFPs, and VCAM1+ CMs purified with magnetic-activated cell
sorting (MACS) were suspended in 20 mL of RPMI1640 medium and injected
into the subrenal space of SCID mice.
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Isolation and Quantification of Exosome
Undifferentiated tetO-CD82-EGFP iPSCs at subconfluency in a 10-cm dish
were cultured in primate ESC medium (ReproCELL) with 10 ng/mL basic
fibroblast growth factor (bFGF) with or without 1 mg/mL Dox for 3 consecutive
days. PDGFRa+ cells at day 5 were recultured in a 6-well plate with serum
(10% FBS) under one of the following conditions for 2 days (days 5–7):
(1) Dox- (negative control), (2) Dox- with Wnt inhibitors (XAV 5 mM + IWP4
2.5 mM) (positive control), or (3) Dox+ with no Wnt inhibitors. The collected
supernatant was centrifuged at 2,000g for 30 min to remove cells and at
12,000g for 1 hr to remove debris. Cell-free supernatant was passed through
a 0.22-mm pore filter (Merck Millipore) and finally submitted to ultracentrifu-
gation at 100,000 g (Beckman Coulter Optima L-100XP ultracentrifuge, Beck-
man Coulter) for 1 hr at 4C. After discarding the supernatant, pellets were
eluted in PBS with 40 mM HEPES and 100 mM KCl (100–200 mL) and
analyzed.
Western Blotting
Nuclear and cytoplasmic fractions were extracted from undifferentiated
iPSCs with the NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit
(Thermo Fisher Scientific). Exosomes were lysated with radioimmunoprecipi-
tation assay (RIPA) buffer (Thermo Fisher Scientific) and supplemented with
protease inhibitor cocktail (Roche). The protein concentration was quantified
by the Protein Assay Bicinchoninate Kit (Nacalai Tesque). Equal amounts of
proteins from the nuclear and cytoplasmic fractions and proteins from exo-
somes adjusted with exosome particle numbers were examined for western
blotting.
DATA AND SOFTWARE AVAILABILITY
The accession number for the microarray data reported in this paper is Gene
Expression Omnibus: GSE90000. The accession numbers for the flow cytom-
etry data reported in this paper is Flow Repository: FR-FCM-ZYEA, -ZYDL,
-ZYDM, -ZYDN, -ZYDX, -ZYDP, -ZYDQ, -ZYDR, -ZYDS, -ZYDT, -ZYDU,
-ZYDV, -ZYEY, -ZYE2, and -ZYE3. The accession number for the full-length
human CD82 cDNA reported in this paper is NCBI: NM_002231.
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